# Eli Radiopharma

> Hangzhou radiopharmaceutical developer advancing neurological PET imaging diagnostics and experimental cancer radiotheranostics.

## Why it is interesting

A November 12, 2026 issuer-announced Series A of almost €54M (estimated conversion, not an exact round figure) finances preclinical programs and early clinical development. The important distinction is that its ELI-101 neurological PET tracer has trial authorization, while most therapeutic candidates still face IND, human safety, dosimetry and efficacy gates; no marketed drug, revenue, company valuation or commercial pricing is substantiated.

## Profile

- **Latest funding:** Series A — almost €54M (converted estimate; not exact) (November 12, 2026)
- **Latest known valuation:** Not publicly disclosed
- **Total disclosed equity funding:** Not publicly disclosed
- **Stage:** series-a
- **Status:** private
- **Industries:** N/A
- **Coverage:** full
- **Last updated:** 2026-11-12
- **Latest funding investors:** Huagai Capital, Bayland Capital, Boyu Ventures, Delian Capital, InnoPinnacle Fund, Haibang Venture, Bairui Capital, Shenzhen Angel FOF Management, Grand Flight Investment

## Key facts

- November 12, 2026: Series A announced at almost €54M using November 11 ECB FX as a converted upper reference; the issuer reports a 'nearly' amount, not an exact sum.
- Huagai Capital led the Series A; Bayland Capital was co-lead. Additional investors and participating existing holders are identified in the November 12 issuer release.
- ELI-101 is a neurological F-18 PET diagnostic candidate with clinical-trial authorization; this does not mean marketing approval or an established diagnostic service.
- ELI-301, ELI-411 and ELI-601 are experimental solid-tumour radiotheranostic programmes. Multiple targets are approaching IND filing, not necessarily in human trials.
- Earlier separate announcements: €13.2M approximate angel funding (December 2024); more than €12.0M converted Angel+ financing (September 2025); almost €12.6M converted new financing (March 2026). These figures use each original disclosure date's exchange rate and are not reclassified as Series A.

## Funding history

- Series A · almost €54M (converted estimate; not exact) · November 12, 2026
  Source: https://www.eliradiopharma.com/en/newsroom/press-release/29
- New financing (stage not disclosed) · less than about €12.6M (converted upper reference) · March 12, 2026
  Source: https://www.eliradiopharma.com/en/newsroom/press-release/28
- Angel+ (separate extension) · more than about €12.0M (converted lower reference) · September 25, 2025
  Source: https://www.eliradiopharma.com/en/newsroom/press-release/2
- Angel · about €13.2M (converted estimate) · December 24, 2024
  Source: https://www.eliradiopharma.com/en/newsroom/press-release/1

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** November 12, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

---
Source: https://venturecapitaltracker.com/startup/eli-radiopharma